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Abstract: Diarrhea is a common clinical manifestation of HIV infection regardless of whether 
the patients have AIDS. HIV and malnutrition tend to occur in the same populations, the 
underprivileged and resource-poor. Malnutrition increases severity and mortality of infection. 
Occurrence of chronic diarrhea in HIV-infected patients, gut status and pathogenic agents, 
nutritional  status  and  the  crucial  role  of  nutrition  are  reviewed.  Bovine  colostrum-based 
food can be useful for managing chronic diarrhea in HIV-infected patients, enhancing both 
nutritional and immunological status.
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Introduction
Infection with HIV imposes monumental suffering on afflicted individuals, and in the 
developing world in particular it places a great burden on the medical system. It is 
generally estimated that close to 100% of HIV-positive patients in the developing world 
may suffer from chronic diarrhea, as estimated on a cumulative life-time incidence, but 
the situation in the developed world is better, where a lower percentage of HIV-positive 
patients suffer from diarrhea.1 It is well known that HIV destroys the immune system 
and renders patients susceptible to opportunistic infections. The virus also leads to 
enteropathy, causing a partial villous atrophy with subsequent malabsorption.2
Patients are usually diagnosed with diarrhea when three or more defecations occur   
per day; chronic diarrhea is diagnosed when this pattern is sustained for more than 
3 months. Chronic diarrhea is not a life-threatening condition, but it can severely diminish 
quality of life. In conditions of poor sanitation it places a particularly heavy psychologi-
cal and social burden on afflicted patients. Chronic diarrhea in HIV patients is also an 
AIDS-defining condition, according to World Health Organization (WHO) criteria.
Etiological pathogenic agents
In a situation where immunodeficiency develops in HIV-infected individuals, one 
of the hardest-hit organs is the intestine. First, the enterocytes can undergo atrophy, 
as a result of the HIV virus infecting the enterocytes and damaging their function.2,3 
Second, as the intestine is the largest immunological organ in the body, destruction 
of immunocompetent cells in the intestine will cause intestinal dysfunction, which is 
among several symptoms observed in diarrhea.
Numerous studies have shown that diarrhea in HIV/AIDS can be caused by   common 
pathogens, including viruses, fungi, bacteria and helminthes. What also   complicates HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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the situation is that, as well as infection by regular pathogens, 
the risk of infection by opportunistic agents increases as the 
patients become immunocompromised.4–7 There is however 
no specific mix of pathogens and opportunistic agents present 
in HIV-associated diarrhea, but the enteric pathogens vary 
from patient to patient and from country to country.
One  pathogen,  which  in  immunocompromised 
HIV-positive individuals can cause chronic diarrhea, is 
  Cryptosporidium. In immunocompetent individuals this 
infection is usually self-limiting, but not in HIV-positive 
immunocompromised individuals. Generally, no effective 
treatment of chronic diarrhea in HIV-positive immunocom-
promised individuals is available, but the mainstay of treat-
ment is treatment with antiretroviral therapy (ART).
Numerous studies have documented the pathogens that 
can be found in patients with HIV-associated diarrhea.4–7 
The consensus seems to be that all known pathogens 
and   intestinal opportunistic agents can cause chronic 
  diarrhea. A diagnostic work-up is needed for each patient, 
if possible. The work-up can be limited to fecal cultures 
and   microscopy, but may also include rectal and/or other 
intestinal biopsies.4–7
Some studies report high yields of identified causative 
agents while others report low figures. Diarrhea is not 
life-threatening, but can severely hamper daily activities 
and lower quality of life. Diagnostic efforts should be 
made to try to find the causative agent and to treat with 
antibiotics and other specific therapies if possible. One 
study   suggested that in immunocompetent individuals, 
defined as those with a CD4+ count of .200/µL, the 
infecting agents were ordinary pathogens, while in 
  individuals with a CD4+ count of ,200/µL, the infecting 
agents were opportunistic agents.8
However, the mainstay of therapy in chronic diarrhea of 
HIV-positive individuals in countries where it is economi-
cally and socially feasible, is treatment with highly active 
ART (HAART).
The risk of chronic diarrhea in HIV-positive patients 
has been reduced dramatically where HAART is acces-
sible, and the decision to introduce HAART is now taken at 
higher CD4+ levels. However, HAART is associated with 
lipodystrophy, which in turn is related to insulin resistance 
and its metabolic complications, such as impaired glucose 
tolerance, diabetes and hypertriglyceridimia.9–11
The pivotal role of CD4+ levels
As the HIV infection progresses and the viral load increases, 
the CD4+ count will decrease. CD4+ lymphocytes are 
T-helper cells, and are directly struck in the HIV virus attack 
as the HIV virus enters these through the CD4+ receptor. 
After entering these key cells in the immunological defense 
system, the HIV virus rapidly proliferates and destroys these 
cells. Where the CD4+ count is ,200/µL, AIDS exists by 
definition.
A variety of ARTs are now available, which can decrease 
the viral load and increase the CD4+ count. In affluent 
societies HIV infection is not considered a deadly disease, 
but a chronic illness, which demands constant and varied 
antiretroviral medication to slow down virus replication, 
with the goal of achieving a low number of viral copies in 
the blood and a reciprocally high number of CD4+ cells.12,13 
This is however not possible in developing countries, where 
nutrition and sanitation are poor, which increases the risk of 
protracted chronic diarrhea.
Although at one predetermined CD4+ level there is an 
indication for treatment with HAART, different studies 
suggest that with proper nutritional support the chances 
of HAART treatment reducing disease burden increase.14 
Also, as HAART treatment can induce adverse effects, 
especially metabolic side effect, and also diarrhea, the 
longer the introduction of HAART is postponed the better. 
So postponing the introduction of HAART by introducing 
a nutritional treatment of a varied and healthy diet, which 
is rich in micronutrients, or by adding nutritional additives, 
for example, preparations rich in colostrum, could be very 
rewarding.
The role of nutrition in hindering 
progression of HIV disease
There is good consensus that malnutrition has a negative 
impact on survival in HIV disease, even when ART is at 
hand. In addition, malnutrition at introduction of ART is 
associated with early mortality,14–18 with a low body mass 
index as its independent predictor.19
Nutritional support can result in restored intestinal 
function20 and weight gain in HIV-infected children.21 The 
patients reported in both these studies were enrolled before 
HAART was available. An increase in CD4+ cell numbers 
could be observed in one of these studies,20 especially if 
nutritional support were provided before a terminal stage of 
HIV infection, whereas nutritional support of children with 
advanced HIV infection reported by Rollins et al21 resulted 
in sustained weight gain but not improved CD4+ count or 
survival.
One question that has attracted a great deal of attention 
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wasting in HIV disease. Wasting is probably caused by 
several mechanisms, where diarrheal disease caused by 
enteric pathogens, opportunistic infection and enterocyte 
destruction are among the causative factors. One study 
from Tanzania showed that a combination of vitamins 
C and E and vitamin B complex slowed weight decrease 
in HIV-infected women and delayed HIV progression 
  significantly.22 Another study, which was a randomized 
trial comparing vitamin supplementation with placebo 
on HIV disease progression, showed that multivitamins 
increased CD4+ and CD8+ counts and lowered viral load 
compared with placebo.23 Thus, in this study multivitamins 
slowed progression of HIV disease. However, a Cochrane 
study conducted by Irlam et al found no conclusive evi-
dence that micronutrients reduce morbidity or mortality 
in HIV-infected adults but the authors concluded that the 
WHO recommendations for micronutrient supplementations 
should be followed.24
However, micronutrient supplementation is just one 
part of good general nutrition and the overall recommenda-
tion should be that HIV-infected patients, if it is socially 
and economically feasible, should have a good and varied 
nutritional intake.
Many publications can be found on the effect of micro-
nutrient supplements on HIV progression in both children 
and adults,22,23,25,26 but there are few reports on the role of 
macronutrients for improving survival of HIV-infected 
individuals. However, it has been shown that HIV-positive 
patients with opportunistic illness have increased rates of 
catabolism and require greater protein intake to minimize 
loss of lean body mass.27 An anticatabolic effect of nutri-
tional supplements (containing 2510 kJ, complete macro- 
and micronutrients) combined with dietary counseling in 
HIV-infected subjects was reported by Berneis et al.28 The 
diminished whole body protein catabolism resulted in a 
change of body composition (increased lean mass, decreased 
fat mass). Current evidence supporting macronutrients 
supplementation for malnourished HIV-infected adults has 
been recently reviewed by Koethe et al.29 The authors sug-
gested a range of variables for future macronutrient-based 
trials for malnourished HIV-infected persons in order to 
succeed with ART programs.
The role of a structurally intact 
small intestine
As early as 1984, Kotler and associates described an 
HIV-associated enteropathy with structural resemblance 
to celiac disease.3 There is thus a reduced villous height 
in HIV infection and also a CD4+ mucosal lymphopenia 
and an increase in CD8+ lymphocytes. Further, there is 
an enhanced intestinal permeability, possibly leading to a 
greater influx of lipopolysaccharides, which are bacterial 
antigens from Gram-negative bacteria.30 This can clearly 
be a factor that causes diarrheal disease and exacerbates or 
causes malnutrition.
Role of bovine colostrum  
in treatment of HIV- 
associated diarrhea
A few observational studies have been published on the effect of 
bovine colostrum preparations in HIV-associated diarrhea.31–36 
In one of these a substantial therapeutic effect was reported 
in 25 patients, 40% of whom had a complete remission and 
24% a partial remission of diarrheal disease post treatment.32 
In other studies, the efficacy of treatment with colostrum 
preparations was reported in   Cryptosporidium-associated 
diarrhea in patients with AIDS.34–36
Bovine colostrum is the first milk the lactating cow 
gives to the suckling calf during the first days of life. Its 
composition is quite different from that of ruminant milk 
in established lactation and is characterized by its very high 
level of several bioactive components: immunoglobulins, 
growth factors, some whey proteins and proteinase inhibitors, 
vitamins and minerals. The biological function of colostrum 
is to, through its composition, provide the calf with passive 
immunity, support calf growth and prevent gastrointesti-
nal infections until the calf’s own immune system is fully 
functional.
The immune system of the newborn has been shown to 
be stimulated by colostrum which works to speed up the 
maturation of B-lymphocytes. Colostral immunoglobulins, 
the amount of which can be 50–250 times higher than in 
milk during established lactation,37 may both treat and 
prevent viral and bacterial infections. In addition, colostrum 
contains lactoferrin, a protein that has been shown to transport 
essential iron to hematopoietic cells and prevent harmful 
viruses and bacteria from getting the iron they need for their 
growth. Bovine colostrum is also known to contain growth 
factors, the major forms of which are IGF-1 and TGF-β2, the 
composition of which is identical to that found in humans. 
They can promote mucosal recovery and gut integrity in 
patients with severe diarrheal illness. A study in rats showed 
that bovine colostrum preparation can heal the injurious 
effects of nonsteroidal anti-inflammatory drugs, which cause 
increased gastrointestinal permeability.38 High amounts of 
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known, have also been reported in colostrum.39 Low levels 
of plasma Zn and Se are associated with the deterioration of 
immune system and higher mortality.40,41
We have used ColoPlus® IMCARE (ColoPlus, Malmö, 
Sweden), a therapeutic food product based on bovine 
colostrum powder, in studies on HIV/AIDS patients 
suffering from diarrhea and malnutrition. The product 
was developed for this application. The nutritional value 
of   ColoPlus® IMCARE is shown in Table 1. ColoPlus® 
IMCARE has been tested in clinical studies on HIV-positive 
patients in two settings in Nigeria42 and Uganda.43 Both 
studies showed that ColoPlus® IMCARE can alleviate 
diarrheas, increase body weight and induce significant 
increase in CD4+ levels.
ColoPlus® IMCARE is made and delivered in powder 
form and has to be mixed with water to obtain a porridge 
suitable for consumption. No side effects have been reported. 
The proposed portion size, suitable for flexibility of use and 
handling, is 25- or 50-g sachets.
ColoPlus® IMCARE consists of two parts, a bioactive 
part (colostrum) and a vehicle. The vehicle is composed 
of organic particulate matter, which is used to slow down 
and control the time required to empty the stomach, thus 
prolonging transit time of bioactives through the digestive 
tract, increasing contact time with the mucosal surface of 
the gastrointestinal tract and causing local immunological 
response. Survival and resistance of the bioactive parts in 
the gastrointestinal tract are also increased.
Colostrum powder quality is of crucial importance for 
the therapeutic effect of the product. Industrial processing 
of colostrum for ColoPlus® IMCARE manufacture is 
carried out carefully to prevent its balanced system from 
distortion of bioactive peptides and protein denaturation. 
In product formulation, a principle of “entire colostrum 
system” is used. All the bioactive components in colostrum 
act synergistically in such a way that improves the   overall 
effect of each individual component. Without further 
fractionation, some of the components that make up 
colostrum, such as carbohydrates, proteins and salts, can 
protect more sensitive components of colostrum from 
inactivation during the conventional processing used in 
the dairy industry.44 The quality is determined by the 
IgG content, which is an established marker for liquid 
colostrum quality, with growth factors being positively 
correlated with Ig levels.44
To ensure that the effects of ColoPlus® IMCARE were 
sustained, CD4+ count, body weight, and frequency of bowel 
movements were measured in the two above mentioned 
  studies, 2 and 5 weeks after termination of ColoPlus therapy. 
In both studies a sustained effect of ColoPlus, as measured 
by the above mentioned parameters, was apparent. The 
therapeutic effect of ColoPlus® IMCARE was shown to last 
for at least 5 weeks.
Thus, in these studies ColoPlus® IMCARE not only 
significantly increased CD4+ level but also alleviated diar-
rhea and sustained weight gain. Thus, this colostrum-based 
food product, through its bioactive content combined with 
micronutrients and high quality macronutrients, such as 
essential amino acids and carbohydrates, could improve 
both the immune and nutritional status in HIV-infected 
individuals.42,43
Challenges and future directions
Challenges for the future are partly socioeconomic and 
partly medical. Socioeconomically, the overall aim for 
HIV-associated diarrhea should be that all disease-stricken 
individuals should have access to HAART. Of course, a 
proper medical investigation and directed therapy should 
be undertaken for each individual. Once this is in place, 
the challenge is to ensure that antiretroviral agents can act 
optimally. In doing so, there should be a high emphasis on 
good and adequate nutritional therapy. Also, we believe that 
special nutritional regimes such as colostrum-based therapies 
could have a role in this situation, especially as an adjunct to 
treatment of HIV-associated diarrhea.
However, the world’s resources are limited, especially 
in the developing countries. One priority would under such 
circumstances is to try to postpone the need for   antiretroviral 
agents or HAART by introducing adequate nutritional sup-
port. Colostrum-based remedies can have a crucial role in 
sustaining CD4+ levels and can also diminish viral load, 
thereby saving time until the introduction of antiretroviral 
agents. Adverse effects, especially metabolic, of ART, 
Table 1 Nutritional value of ColoPlus® IMCARE
Energy value 1650 kJ/360 kcal
Protein, g 23.0 ± 2.0
IgG, g 7.4 ± 1.2
Fat, g  2.0 ± 0.2
Carbohydrate, g 69.0 ± 2.0
Lactose, g 6.0
Sucrose, g 4.0
Ash, g 2.0 ± 0.2
Dry matter, g 96.0 ± 0.5
Note: values are per 100 g dry product.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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including HAART, means that their introduction should be 
delayed as long as possible.
An ongoing trial, the CORAL study, is measuring the 
effect on CD4+ counts of combining hyperimmune bovine 
colostrum with the antiretroviral drug raltegravir.45
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